Coherus BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary

Coherus Oncology

10/03/2025 21:46

Coherus BioSciences Inc CHRS.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -62 cents.  The mean expectation of eight analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -23 cents to 6 cents per share.

Revenue fell 40.8% to $54.14 million from a year ago; analysts expected $47.27 million.

Coherus BioSciences Inc's reported EPS for the quarter was a loss of 44 cents​.

The company reported a quarterly loss of $50.7 million.

Coherus BioSciences Inc shares had fallen by 24.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 3.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Coherus BioSciences Inc is $7.00

This summary was machine generated from LSEG data March 10 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.13
-0.28
Missed
Sep. 30 2024
-0.13
-0.01
Beat
Jun. 30 2024
-0.29
-0.14
Beat
Mar. 31 2024
-0.24
-0.32
Missed